skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

8 Total results for product and free and sample content found

Scrip

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

By Ian Haydock 27 Nov 2020

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.

Topic Parkinson's Disease

Scrip, In Vivo, Pink Sheet, Medtech Insight

What actually keeps biopharma execs up at night?

06 Sep 2017

What actually keeps biopharma execs up at night?

What actually keeps biopharma execs up at night? Take our quiz to find out. 

Topic Deals Diseases Drug Development Landscape FDA Medtech Personalized Medicine Parkinson's Disease Reimbursement

Emerging therapies in Parkinson’s Disease

23 Jul 2017

Emerging therapies in Parkinson’s Disease

Thirty-five drugs are presently available in multiple global markets for Parkinson’s disease (PD) patients.

Topic Parkinson's Disease

Scrip

Prexton CEO on future for novel Parkinson's therapy

11 Apr 2017

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's technology and its future.

Topic Parkinson's Disease

Datamonitor Healthcare

After several setbacks, Xadago has received a less than ideal FDA approval in Parkinson’s disease

By Stephanie Yip 27 Mar 2017

On 21 March 2017, Newron Pharmaceuticals and its partners Zambon and US WorldMeds announced the approval of Xadago (safinamide) for the treatment of Parkinson’s disease (PD) as an add-on therapy to levodopa/carbidopa for patients experiencing “off” periods (BusinessWire, 2017; FDA press release, 2017). This approval was long-awaited by Newron and its US partner, US WorldMeds, as it followed numerous earlier US regulatory setbacks. Newron and its partner are now looking to successfully launch Xadago, but the US approved label fell short of ideal as it did not extend to early-stage PD patients receiving dopamine agonists  

Topic Diseases Parkinson's Disease

Datamonitor Healthcare

Positive Phase III data for CVT-301

14 Feb 2017

Positive Phase III data for CVT-301 confirm its potential as a new rescue therapy for fluctuating Parkinson’s disease patients

Topic Parkinson's Disease

Datamonitor Healthcare

Ensure your Successful Entrance into the Parkinson’s Disease Market

By Daniel Chancellor 02 Aug 2015

Ensure your Successful Entrance into the Parkinson’s Disease Market

Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.

Topic Parkinson's Disease

Raise Awareness for Parkinson's Drug Development on Moving Day

By Laurie Withington 30 Apr 2014

Raise Awareness for Parkinson's Drug Development on Moving Day

A report that analyses the current clinical development landscape for Parkinson's Disease

Topic Parkinson's Disease

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: